During the past decade, Endocrine Research Solutions, Inc. conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 20 clinical trials were completed, i.e. on average, 76.9% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 11 clinical trials were completed. i.e. 78.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Endocrine Research Solutions, Inc." #1 sponsor was "Medtronic Diabetes" with 10 trials, followed by "AstraZeneca" with 8 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Gan and Lee Pharmaceuticals, USA" with 3 trials sponsored and "Mannkind Corporation" with 3 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Endocrine Research Solutions, Inc." #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Integrated Medical Development" with 1 trials as a collaborator, "Integrium" with 1 trials as a collaborator and "Jaeb Center for Health Research" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Endocrine Research Solutions, Inc." are "Type 1 Diabetes" (7 trials), "Type 2 Diabetes" (7 trials), "Type 1 Diabetes Mellitus" (6 trials), "Diabetes Mellitus, Type 1" (5 trials) and "Diabetes Mellitus" (4 trials). Many other conditions were trialed in "Endocrine Research Solutions, Inc." in a lesser frequency.

Most popular intervention types in "Endocrine Research Solutions, Inc." are "Drug" (28 trials), "Device" (13 trials), "Biological" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Dapagliflozin" (5 trials), "Saxagliptin" (3 trials), "Gan & Lee Insulin Glargine Injection" (2 trials) and "Insulin Degludec" (2 trials). Other intervention names were less common.

The vast majority of trials in "Endocrine Research Solutions, Inc." are 44 trials for "All" genders.

Currently, there are NaN active trials in "Endocrine Research Solutions, Inc.". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Endocrine Research Solutions, Inc., 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Endocrine Research Solutions, Inc., 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 11 trials that are defined as “Not Applicable".